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Abstract
Objective The objective of this study was to assess the emerg-
ing biochemical markers of arterial remodeling in patients
with morbid obesity before and after surgical treatment and
to compare the results to a control group.
Material and Methods The prospective study included 40
patients with BMI 47.73±6.18 kg/m2, qualified for elective
bariatric surgery and re-examined 6 months after the surgery.
The control group consisted of non obese, age and sex
matched 15 subjects. Following laboratory examinations were
performed in all patients: basic laboratory examinations,
MMP-2, MMP-9, adiponectin, PAI-1, CD40L, E-selectin.
Results Examination of patients 6 m after bariatric surgery
revealed a 34.57±9.71 reduction in excess body weight.
Comparison of the study group at two time points revealed
differences in adiponectin, MMP-2 and MMP-9 levels.
Hypoadiponectinemiawas observed in 35%patients 6months
after bariatric surgery compared to 90 % patients before the
surgery. In addition, a strong correlation was observed be-
tween body fat mass and adiponectin levels (r=−0.504,
p=0.055). Moderate correlations were demonstrated between
E-selectin levels and BMI (r=0.361; p=0.022), and
metalloproteinase-9 levels (r=0.326; p=0.040). In addition,
strong relationship was demonstrated between MMP-2 and
MMP-9 (r=0.502; p=0.001), and moderate between MMP-2
and adiponectin levels (r=0.449; p=0.003). MMP-9 levels
were moderately correlated with HDL-cholesterol levels (r=
0.316; p=0.046).
Conclusions Assessment of laboratory markers of arterial
remodeling and metabolism suggest their adverse changes in
patients with morbid obesity. However, body mass reduction
due to bariatric surgery decreases inflammatory status, im-
proves biochemical markers of arterial remodeling as well as
to beneficial changes in the metabolism.
Keywords Atheroslerosis . Bariatric sugery .Morbid
obesity . Emergingmarkers . MMP
Obesity is an established risk factor for a number of cardio-
vascular disorders. The adipose tissue is a complex, metabol-
ically active organ and a source of pro-inflammatory cyto-
kines. Hormones produced by the adipose tissue play a key
role in the energy balance and the metabolism of carbohy-
drates and lipids [1]. Due to the activity of pro-inflammatory
cytokines, individuals with excess adipose tissue experience
chronic inflammation which leads to progressive dysfunction
in the endothelium, recruitment of further inflammatory cells,
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remodeling of the blood vessels [2–4] with the development
of intermediate plaque. Activation of inflammatory cells pro-
ducing cytokines and chemokines leads to the development of
complex plaque [3].
Development of atherosclerosis involves activity of extra-
cellular matrix metalloproteinases (MMP-2 and MMP-9),
adiponectin, E-selectin, PAI-1, and CD40L. Extracellular ma-
trix metalloproteinases are involved in remodeling of extra-
cellular matrix and basal membranes. Disturbed equilibrium
between MMPs and their inhibitors (tissue inhibitors of me-
talloproteinases, TIMPs) [4] and α-2-macroglobulin leads to
enhanced proteolysis and endothelial damage or to accumu-
lation of matrix constituents [5]. MMPs were demonstrated to
play an important role in the atherosclerotic process, modula-
tion of adipogenesis, [6] remodeling of the walls of blood
vessels and myocardium [7, 8].
Adiponectin is a polypeptide hormone, produced and se-
creted into blood only by adipose tissue cells [9]. According to
many authors, production of adiponectin is, in contrast to
other hormones originating from the adipose tissue, negatively
correlated with the body weight, visceral fat, and BMI, [10]
although not all studies have confirmed this hypothesis
[11–14]. Abbasi et al. demonstrated that a small drop in body
weight due to non-surgical methods does not significantly
affect the adiponectin levels; [13] In clinical practice,
hypoadiponectinemia is considered to be a predictor of type
II diabetes, lipid disorders, arterial hypertension and non-
alcoholic liver fatty liver disease. Schondorf et al. determined
the reference adiponectin levels to be in the range of 7–12 mg/
L. Values lower than 7 suggest hypoadiponectinemia and are a
strong indicator of complications within the cardiovascular
system [15, 16].
The CD40 ligand (CD40L) belongs to the family of tumor
necrosis factor (TNF alpha) cytokines. It is an element of the
CD40/CD40L transmitter system. It should be highlighted
that studies published to date suggest elevated sCD40L levels
in type II diabetes, [17–19], metabolic syndrome, [17, 20].
Data on the relationship between CD40L levels and obesity
and morbid obesity are ambiguous [21, 22].
E-selectin, is a membrane protein from the selectin group.
Data on the relationship between E-selectin levels and body
weight/BMI are ambiguous. Palomo et al. demonstrated no
difference between E-selectin levels in a group of metabolic
syndrome patients and patients without metabolic syndrome
[20]. Hanusch-Enserer et al., who conducted a study in a
group of 32 patients with morbid obesity subjected to LAGB
demonstrated that E-selectin levels were positively correlated
with BMI both before and after the surgery [23].
Elevated plasminogen activator inhibitor-1 (PAI-1)
levels, were observed in patients with obesity. It was
suggested that bariatric surgeries lead to positive
outcomes, as PAI-1 levels in patients after the surgery
are lower than before the surgery [24].
Objectives
The objective of this study was to assess the emerging bio-
chemical markers of arterial remodeling in patients with mor-
bid obesity before and after gastric bypass surgery and to
compare the results to a control group consisting of individ-
uals with normal body weight.
Methods
The prospective study included 40 female patients with
morbid obesity, BMI 47.73±6.18 kg/m2, qualified for
elective gastric bypass surgery and re-examined 6 months
after the surgery. Patients with the history of myocardial
infarction or with significant valvular heart disease,
chronic renal disease (GFR<60 ml/min/1,73 m2), chronic
hepatic insufficiency, or chronic obstructive pulmonary
disease, smokers (>20 cigarettes/day), and patients with
obstructive sleep apnea (acute, AHI ≥ 30) were excluded
from the study.
The control group consisted of non obese, age and sex
matched 15 subjects.. Anthropometric measurements and
laboratory analyses were performed in all study subjects.
Body weight, fat body mass and lean body mass values
were determined using Tanita TBF-300 Body Composi-
tion Analyser based on electric bioimpedance measure-
ments. Ideal body weight (IBW) was calculated accord-
ing to the following formula: (age in cm–100)–10 %;
excess body weight (EBW) was calculated according to
the following formula: current body weight–ideal body
weight; % excess weight loss (%EWL) was calculated
according to the following formula: (body weight before
surgery–body weight 6 months after surgery)/ excess
body weight before surgery x 100.
Following laboratory examinations were performed in all
patients: complete blood counts, lipid profile, creatinine
(mg/dL), hsCRP (mg/L), HbA1C (%), serum glucose (mg/dl)
and serum insulin (μIU/mL) by immunochromatography,
MMP-2 – Ray Biotech ELISA kit, MMP-9 – Ray Biotech
ELISA kit, adiponectin – Teco Medical ELISA kit, PAI-1 –
Biovendor ELISA kit, CD40L – GEN PROBE diaclone
ELISA kit, E-selectin – GEN PROBE diaclone ELISA kit.
The study protocol was approved on 31 March 2009 by the
Local Bioethics Committee.
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Statistical Analysis
Quantitative variables were analyzed using standard descrip-
tive statistic measures: means, standard deviations for normal
distribution variables and medians and ranges for non-normal
distribution variables. The hypothesis of variable distribution
being consistent with normal distribution was tested for quan-
titative variables. To this end, Shapiro-Wilk’s test and Q-Q
plot test were used. When distribution of a particular variable
was normal, the hypothesis of the means in two study groups
being equal was examined using the Student’s t-test.
Wilcoxon’s test for independent samples was used to compare
two groups in case of parameters demonstrating deviations
from normal distribution. The analysis of quantitative param-
eters of management involved the following dependent sam-
ple tests: Student’s t-test for normal distribution variables and
Wilcoxon’s test for non-normal distribution variables. Corre-
lations between quantitative variables involved Pearson’s co-
efficient for normal distribution variables and Spearman’s
coefficient for non-normal distribution variables. The relation-
ships between qualitative variables were studied in contingen-
cy tables using the chi-square test or Fisher’s exact test when
the expected values in table cells were not high enough (i.e.
above 5). The analysis of changes in qualitative parameters
during the treatment involved the McNemar’s test for the
symmetry of related samples. The level of statistical signifi-
cance was established at p<0.05. Calculations were per-
formed using the SAS 9.2 software.
Results
Overall Clinical Characteristics of Morbid Obesity Patients
A total of 40 patients with pathological obesity, aged 36.4±
9.0 years were included into the study. All patients were re-
examined approximately 6 month after the surgery Table 1
presents the anthropometric parameters of patients qualified
for the surgery and patients in the control group.
Arterial hypertension was diagnosed in 38 (95 %)
patients. Initially 30 (75 %) patients received 2 or more
hypotensive drugs (including ACE inhibitors and a di-
uretic); while 8 (20 %) patients received only one
hypotensive drug (ACE inhibitor). Pre-diabetes was di-
agnosed in 11 (27.5 %) patients, including impaired
fasting glucose in 6 patients (15 %) and impaired glu-
cose tolerance in 7 (17.5 %) patients [25]. Both of these
abnormalities were observed simultaneously in 2 pa-
tients (5 %). Patients diagnosed with type 2 diabetes
were excluded from the study. Lipid metabolism disor-
ders were observed in 22 (55 %) patients, while 8
(20 %) patients were diagnosed with obstructive sleep
apnea of not more than moderate intensity.
Assessment of Blood Chemistry Parameters in Patients
with Morbid Obesity
Table 2 presents the blood chemistry parameters observed in
patients with morbid obesity
Comparison of Blood Chemistry Parameters in the Group
of Patients withMorbid Obesity (OB1) and the Control Group
(CG)
Table 3 presents comparison of blood chemistry parameters in
the group of patients with morbid obesity and the control
group
Assessment Pre- and Post-Surgery Anthropometric
Parameters in Patients with Morbid Obesity
Table 4 presents the comparison of anthropometric parameters
in the study group before the bariatric surgery and 6 months
after bariatric surgery.
Table 5 compares the study results comparing blood chem-
istry parameters in patients before bariatric surgery and
6 months after bariatric surgery.
In addition, a strong negative correlation was ob-
served between body fat mass and adiponectin levels
(r=−0.504, p=0.055).
Moderate correlations were found between E-selectin levels
and BMI (r=0.361; p=0.022), MMP-9 levels (r=0.326;
p=0.040). Mutual strong correlation was observed be-
tween metalloproteinases MMP-2 and MMP-9 (r=0.502;
p=0.001). In addition, (“strong” removed)moderate relation-
ship was demonstrated between MMP-2 and adiponectin
levels (r=0.449; p=0.003). On the other hand, MMP-9 levels
were moderately correlated, as mentioned previously, with E-
Table 1 Anthropometric parameters of patients qualified for bariatric
surgery (OB1) and the control group (CG)
OB1 (n=40) CG (n=15) p
Body weight (kg) 132.03±18.42 60.73±5.12 <0.0001
BMI (kg/m2) 47.73±6.18 21.61±1.41 <0.0001
FAT (%) 49.15±3.83 25.13±4.88 <0.0001
FFM (kg) 66.78±7.84 45.37±3.7 <0.0001
BSA M (m2) 2.47±0.20 1.68±0.09 <0.0001
EBW (kg) 72.34±16.75
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selectin levels (r=0.326; p=0.040) as well as with HDL-
cholesterol levels (r=0.316; p=0.046).
Changes in Studied Parameters 6 Months After Bariatric
Surgery
Examination of patients 6 months after bariatric surgery re-
vealed a 34.57±9.71 kg reduction in excess body weight. This
change was accompanied by changes in laboratory parame-
ters. Statistically significant changes and changes important
for presentation of the results are presented in Tables 6 and 7.
Discussion
The study assessed, in a non-invasive manner, emerging
markers of atherosclerosis in patients with morbid obesity as
compared to the control group with normal body weight, as
well as the efficacy of gastric bypass surgery of obesity in
normalization of these parameters. A total of 40 female pa-
tients with morbid obesity, meeting the qualification criteria
for bariatric surgery, were qualified for the study [26]. Patients
qualified for gastric bypass surgery were not different from the
control group subjects in age while differing in BMI range for
Table 2 Assessment of blood
chemistry parameters in patients
with morbid obesity
mean ±SD median range
fasting glucose (mg/dL) 90.4 10.19 89 67.0–124.0
fasting insulin (μIU/mL) 17.68 11.29 14.07 5.45–56.33
HOMA-IR 3.89 2.33 3.31 1.14–11.68
creatinine (mg/dL) 0.76 0.16 0.7 0.5–1.3
total cholesterol (mg/dL) 199.15 35.13 197.5 129.0–296.0
HDL-chol (mg/dL) 52.55 10.97 50.5 36.0–86.0
LDL-chol (mg/dL) 120.3 31.59 119.5 52.0–240.0
triglycerides (mg/dL) 124.78 47.7 114 31.0–255.0
hsCRP (mg/L) 10.19 6.92 8.8 1.9–32.02
HbA1C (%) 5.8 0.89 5.65 5.2–6.6
CD40L (ng/mL) 3.63 34.3 1.96 0.02–17.51
E-selectin (ng/mL) 68.49 38.94 56.48 21.87–191.71
Adiponectin (ng/mL) 4,976.34 2,728.36 4,345.94 1,893.15–16,270.60
MMP-2 (ng/mL) 70.15 74.11 46.19 11.23–419.06
MMP-9 (ng/mL) 10,061 4,510.67 8,546.49 2,210.59–30,522.40
PAI (pg/mL) 257,373 175,597 246,291 20,639.20–818,896
Table 3 Comparison of blood
chemistry parameters in the group
of patients with morbid obesity
and the control group
OB1 (median, range) CG (median, range) p
fasting glucose (mg/dL) 89; 67–124 90; 81–102 NS
fasting insulin (μIU/mL) 14.07; 5.45–56.33 6.81; 3.57–12.73 <0.0001
HOMA-IR 3.31; 1.14–11.68 1.61; 0.78–3.02 <0.0001
creatinine (mg/dL) 0.7; 0.5–1.3 0.8; 0.6–0.9 NS
total cholesterol (mg/dL) 197.5; 129.0–296.0 183; 129–233 NS
HDL-chol (mg/dL) 50.5; 36.0–86.0 69; 50–85 <0.0001
LDL-chol (mg/dL) 119.5; 52.0–240.0 105; 52–145 0.04
triglycerides (mg/dL) 114; 31.0–255.0 51; 30–203 0.001
hsCRP (mg/L) 8.8; 1.9–32.02 0.60; 0.1–2.40 NS
HbA1C (%) 5.65; 5.2–6.6 5.60; 5.30–5.80 0.001
CD40L (ng/mL) 1.96; 0.02–17.51 0.56; 0.06–1.77 0.0008
E-selectin (ng/mL) 56.48; 21.87–191.71 54.41; 20.73–110.01 NS
Adiponectin (ng/mL) 4,345.94; 1,893.15–16,270.60 14,548.31; 5,392.68–26,099.29 <0.0001
MMP-2 (ng/mL) 46.19; 11.23–419.06 28.05; 4.31–295.86 0.03
MMP-9 (ng/mL) 8,546.49; 2,210.59–30,522.40 7,304.87; 7,011.3–7,660.98 <0.0001
PAI (pg/mL) 246,291; 20,639.20–818,896 84,523.52; 33,281.73–181,843.26 0.0003
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obvious reasons. When comparing both groups, obese pa-
tients were found to exhibit higher fasting insulin levels and
HOMA index values. In 19 patients with morbid obesity
(48,71 %) fasting insulin levels exceeding 15μIU/mL and
suggesting hyperinsulinemia. At the same time, insulin resis-
tance was diagnosed in 67 % of morbidly obesity patients. No
cases of hyperinsulinemia or insulin resistance were observed
in the control group.
Also according to published reports mean triglyceride and
LDL-cholesterol levels in the group of patients qualified for
the surgery was higher than in the CG while the mean HDL-
cholesterol level was lower than in the CG. Medians of
CD40L, adiponectin, MMP-2,MMP-9, and PAI-1 levels were
higher in the group of morbid obesity patients as compared to
the control group [27–29]. Hypoadinectinemia was diagnosed
in 90 % of patients qualified for the bariatric surgery and in
20 % patients in the control group. This confirms previous
observations suggesting high incidence of lipid metabolism
disorders in obese individuals [30, 31].
After the surgery, following a 6-month follow-up period, a
significant drop was observed in BMI, from 47.73±6.18 kg/
m2 to 35.22±5.20 kg/m2 (p<0.0001), and EBW from 72.34±
16.75 kg to 37.77±13.97 kg (p<0.0001). Significant im-
provement in carbohydrate metabolic parameters was ob-
served following the bariatric surgery. Elevated fasting blood
glucose levels were observed in 6 (15 %) patients in the OB1
group; elevated fasting insulin levels of more than 15 μIU/mL
were initially observed in 19 (48.7 %) of study group patients.
A statistically insignificant drop was observed in the fasting
blood glucose levels (90.40±10.19 mg/dL vs. 85.35±
9.50 mg/dL; NS), highly significant (p<0.0001). drop in
fasting insulin levels was observed; after the follow-up period
of 6 months, fasting hyperinsulinemia was diagnosed only in
6 (15%) patients. A decrease in insulin resistance as measured
by the HOMA-IR index was also observed after the surgery.
Our observations regarding the disturbed carbohydrate metab-
olism were in line with those in the available literature. Also
Krebs et al., when studying a group of morbid obesity patients
Table 4 Comparison of anthropometric parameters of patients 6 months
after bariatric surgery (n=40)
OB1 OB2 p
Body weight (kg) 132.03±18.42 97.46±15.35 <0.0001
BMI (kg/m2) 47.73±6.18 35.22±5.20 <0.0001
FAT (%) 49.15±3.83 38.20±5.66 <0.0001
FFM (kg) 66.78±7.84 59.90±8.92 <0.0001
BSA M (m2) 2.46±0.19 2.12±0.19 <0.0001
EBW (kg) 72.34±16.75 37.77±13.97 <0.0001
Table 5 Comparison of blood chemistry parameters in patients before bariatric surgery and 6 months after bariatric surgery
OB1 (median, range) OB2 (median, range) p
fasting glucose (mg/dL) 89; 67–124 85.00; 66.00–109.00 0.0139
fasting insulin (μIU/mL) 14.07; 5.45–56.33 7.72; 1.67–108.00 <0.0001
HOMA-IR 3.31; 1.14–11.68 1.76; 0.35–24.80 <0.0001
creatinine (mg/dL) 0.7; 0.5–1.3 0.80; 0.5–1.0 NS
total cholesterol (mg/dL) 197.5; 129.0–296.0 191.00; 122.00–257.00 <0.0001
HDL-chol (mg/dL) 50.5; 36.0–86.0 55.00; 38.00–80.00 NS
LDL-chol (mg/dL) 119.5; 52.0–240.0 112.50; 57.00–183.00 NS
triglycerides (mg/dL) 114; 31.0–255.0 88.50; 39.00–235.00 <0.0001
hsCRP (mg/L) 8.8; 1.9–32.02 2.80; 0.4–25.50 <0.0001
HbA1C (%) 5.65; 5.2–6.6 5.35; 4.70–6.10 <0.0001
CD40L (ng/mL) 1.96; 0.02–17.51 2.00; 0.02–13.95 NS
E-selectin (ng/mL) 56.48; 21.87–191.71 54.05; 14.46–239.31 NS
Adiponectin (ng/mL) 4,345.94; 1,893.15–16,270.60 8,972.87; 2,940.06–26,711.11 <0.0001
MMP-2 (ng/mL) 46.19; 11.23–419.06 39.26; 8.90–141.47 0.007
MMP-9 (ng/mL) 8,546.49; 2,210.59–30,522.40 8,024.56; 2,210.59–46,160 0.039
PAI (pg/mL) 246,291; 20,639.20–818,896 167,240.43; 19,175.87–622,270.64 NS
Table 6 Correlations of changes in CD40L levels following bariatric
surgery compared to baseline levels (Δ E-CD40L) with changes in levels
of selected biochemical parameters related to endothelial function
Parameter: Δ CD40L r p
Δ total cholesterol 0.937 <0.0001
Δ LDL-cholesterol 0.854 <0.0001
Δ HDL-cholesterol 0.477 0.0018
Δ PAI 0.431 0.0097
Δ E-selectin 0.4036 0.012
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without concomitant type II diabetes over a similar follow up
period observed no significant changes in fasting blood glu-
cose levels and a statistically significant drop in fasting insulin
levels [32]. Increase in adiponectin levels correlated with the
drop in body weight as the result of bariatric surgery was
demonstrated in a number of studies. In our study material,
hypoadiponectinemia, defined as adiponectin levels of
<7,000 ng/mL was observed in 90 % of patients before the
surgery and 35 % of patients after the 6-month follow-up
period. We believe that this change is worth a particular
mention as, according to observations by Schondorf et al.,
adiponectin levels of less than 7,000 ng/mL are a predictor of
very high risk of cardiovascular complications [15]. In
this study, the change in adiponectin levels was strongly
correlated with the change in hsCRP levels (r=−0.519,
p=0.0008). Therefore, what is very important, the in-
verse relationship between adiponectin and inflammation
expressed as elevated hsCRP levels as described in
numerous studies was confirmed [33].
A number of studies demonstrated that MMP-9 levels
were higher in patients with obesity and in patients with
metabolic syndrome as compared to patients with normal
body weight [27, 28]. Kosmala et al. observed that MMP-
9 levels were strictly correlated with BMI values in obese
patients, [34], while. Derosa et al., Unal et al. and other
researches demonstrated the relationship between MMP-9
and body weight parameters in patients with morbid obe-
sity before bariatric surgery [27, 35, 36] as well as after
significant body weight reduction as a result of bariatric
surgery [37–40]. However, no statistically significant cor-
relation between MMP levels and body weight parameters
was observed in this study. It is also worth mentioning
that a statistically significant drop in MMP-9 levels was
observed along with the reduction in body weight
(8546.49; 2210.59–30522.40 ng/mL vs. 8024.56;
2210.59–46,160 ng/mL; p=0.039).
In a study of 328 subjects (163 morbid obesity patients and
165 control group subjects), Derosa et al. observed that the
activity of MMP-2 was significantly higher in morbid obesity
patients, similar as in the case of MMP-9 [27]. The present
study also demonstrated that the blood levels of MMP-2 in
OB1 group was statistically significantly higher than in
the OB2 group (46.19; 11.23–419.06 ng/mL vs. 39.26;
8.90–141.47 ng/mL; p=0.007) and in the control group.
Therefore, it is worth underline lower probability of
plaque destabilization, after surgery.
Unek et al. examined the relationship between hsCRP
and sCD40L levels and the body weight in a group of
148 patients not suffering from type 2 diabetes. They
observed higher hsCRP and sCD40L levels in obese
patients as compared to overweight or normal weight
patients while also demonstrating a positive correlation
between hsCRP and sCD40L levels and BMI in the
entire study population (r=0.514, p=0.0001 and r=0.283,
p=0.0001, respectively). Guldiken et al. [22] were unable to
demonstrate such correlation between sCD40L levels
and the BMI as well as between the levels of hsCRP
and sCD40L. In our study group, no statistically signif-
icant correlation was observed between the levels of
sCD40L and hsCRP, as well as between changes of
these levels in the follow-up period. However sCD40L
levels currently observed in the OB1 group were similar
to those observed by Schernthaner et al. in the group of
patients with morbid obesity (3.63±4.30 vs. 3.7±1.5 ng/mL)
[41]. One should not overlook highlighting the observed
strong correlation between sCD40L and PAI-1 (r=0.53115,
p=0.0005) as well as moderate correlation between
ΔCD40L and ΔPAI-1 (r=0.43109; p=0.0097) in the
group of morbid obesity patients, which may contribute
to less complications of atherosclerosis, by antypromoting
thrombus formation in ruptured plaque. According to
the available literature, no correlations between the test-
ed parameters have been studied to date in morbid
obesity patients. Hanusch-Enserer et al., who conducted
a study in a similar group of patients, observed a
statistically significant drop in PAI-1 levels upon
follow-up; an insignificant drop was also observed in
the study group in the present study [23].
In a study of 34 patients subjected to bariatric sur-
gery, Hanusch-Enserer et al. observed a drop in CD62E
(E-selectin) levels during a 6-month follow-up period
[23]. In our study group, an insignificant drop in this
parameter was observed (56.48; 21.87–191.71 ng/mL
vs. 54.05; 14.46–239.21 ng/mL).
Conclusions
Assessment of laboratory markers of arterial remodeling
and metabolism suggest their adverse changes in pa-
tients with morbid obesity, which potentially increase
cardiovascular risk. However, body mass reduction due
to bariatric surgery improves biochemical markers of
arterial remodeling parameters as well as to beneficial
changes in the metabolism.
Table 7 Correlations of changes in E-selectin levels following bariatric
surgery compared to baseline levels (Δ E-selectin) with changes in levels
of selected biochemical parameters related to endothelial function
Parameter: Δ E-selectin r p
Δ total cholesterol 0.348 0.0277
Δ CD40L 0.854 <0.0001
ΔMMP-9 0.302 0.0587
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